Am I a Candidate for a Hair Transplant? UK 2026 Guide

Am I a candidate for a hair transplant? You're likely a candidate if four conditions are met: your hair loss is stable, you're over 25, your donor area at the back of the scalp has adequate density (typically over 60 follicular units per cm²), and you don't have an active scarring or autoimmune scalp condition. This guide walks through the four-part candidacy framework used by credentialed UK surgeons, with peer-reviewed sources.

The four-part candidacy framework

Credentialed UK surgeons assess candidacy across four axes. All four need to clear before surgery is appropriate. This guide is informational, not medical advice — definitive candidacy needs in-person examination by a clinician credentialed by BAHRS or ISHRS who can physically assess your donor area and document loss stability.

1. Pattern of loss — patterned (androgenetic) versus diffuse, scarring, or other
2. Stability over time — is the loss progressing or has it stabilised?
3. Donor capacity — does the back of the scalp have enough viable follicles?
4. Absence of contraindications — no active scalp disease, autoimmune flare, or systemic factor that excludes surgery

Failing any one of these makes you a poor candidate even if the others are perfect. A patient with classic Norwood pattern loss, age 35, with normal scalp health but an active flare of alopecia areata is not a candidate this year. A 22-year-old Norwood 5 is not a candidate today even if everything else is fine.

1. Pattern of loss

The transplanted hair only stays permanently if it comes from a "donor-dominant" area — follicles genetically resistant to the hormone (DHT) that causes pattern hair loss.

Surgical patterns:

• Male androgenetic alopecia (AGA), Norwood stages II–IV: standard candidates. Stage V is marginal; stages VI–VII typically not fully restorable. See our Norwood scale guide.
• Female pattern hair loss with preserved donor: candidates if loss is stable and donor area is verifiably unaffected. Less common than male candidacy.
• Localised loss from scarring (burns, trauma, surgery) once scar is mature

Non-surgical patterns:

• Diffuse unpatterned alopecia (DUPA): donor area is itself unstable, so transplanted hair won't stay [1]
• Active alopecia areata: autoimmune; transplanted grafts can be attacked
• Active scarring alopecias (FFA, LPP): inflammation destroys grafts [5, 6]
• Acute telogen effluvium: transient — hair usually regrows on its own [8]

The first job of a consultation is to establish which group you're in. This is the part of candidacy that can't be self-assessed.

2. Stability over time

A diagnosis is a snapshot. Surgery makes sense only if the loss has stabilised — otherwise the transplanted hair sits behind a hairline that continues to recede over the next 5–10 years, producing the "island" effect that ISHRS guidance specifically warns about [3].

The "wait until 25" convention is consensus-based rather than evidence-derived. ISHRS guidelines support waiting to allow the AGA pattern to fully manifest before committing to a permanent surgical placement. UK BAHRS practice often goes further: a 6–12 month documented response to medical therapy (finasteride or minoxidil) for patients under 30 to confirm stability before booking surgery [4].

Stability is documented three ways in UK practice:

If you've had a hair transplant consultation, your surgeon should ideally have at least one of these on file before booking surgery for a patient under 30.

3. Donor capacity

The back of the scalp is the only source of permanent follicles for the transplant. You can't grow new ones. The donor is finite, and surgeons assess capacity before quoting a graft count.

The conventional surgical threshold is >60 follicular units per cm² in the safe donor zone, traceable to Walter Unger's original Safe Donor Zone definition [1]. Below 40 FU/cm² is generally considered too sparse for surgery to produce a satisfying outcome. Modern practice increasingly uses a "total donor capacity" framework that combines:

• Donor density (FU/cm²)
• Hair calibre (thickness of each individual hair shaft)
• Follicular grouping (proportion of 1-hair, 2-hair, 3-hair, and 4-hair units)
• Total safe donor area in cm²

The "Hair Measurement Index" approach is replacing simple density-only assessment in published clinical literature [2].

You can't reliably self-assess donor density from photos. An in-person examination with magnification is required — a phone camera can't measure FU/cm² accurately. Quotes given via WhatsApp without an in-person donor assessment are estimates and may need adjustment after consultation.

4. Contraindications

Several conditions either exclude surgery or require it to be delayed. The major categories from peer-reviewed literature [5, 6, 7, 8]:

This isn't exhaustive. Your medical history matters — disclose it during consultation. The British Association of Dermatologists guidance on primary cicatricial alopecias [5] is the standard UK reference for the scarring conditions.

Female pattern hair loss: a different case

Female pattern hair loss (FPHL) deserves separate consideration. Unlike male pattern loss, FPHL is typically diffuse rather than patterned, which means thinning often extends into the "safe donor zone" at the back of the scalp [11]. Transplanted hair from a miniaturising donor won't reliably stay permanent.

The two clinical scales for FPHL are:

• Ludwig 3-stage scale (1977) [9]: standard reference
• Sinclair 5-point visual scale (2005) [10]: more granular, picks up earlier-stage loss

Surgical candidates among women are those with stable, well-defined pattern loss (often Ludwig I or early II) and a verifiably preserved donor area. Many women are better served by medical management (minoxidil, sometimes off-label finasteride or spironolactone) than by surgery. See our female hair transplant guide and medications guide.

What a credible UK candidacy consultation looks like

A consultation that takes candidacy seriously will include:

1. Donor area examination with magnification (handheld trichoscope or similar)
2. Hair pull test to assess shedding
3. Pattern classification (Norwood for men, Ludwig/Sinclair for women)
4. Stability assessment — review of photos at 6–12 month intervals if available, or instructions to return after a documented trial of medical therapy
5. Medical history review — autoimmune conditions, current medications, prior scalp procedures, current dermatology issues
6. Realistic graft-count estimate — based on actual donor assessment, not a marketing default

A consultation that doesn't include a physical donor examination is not a real candidacy assessment. Be wary of clinics that quote a graft count and price by WhatsApp photos alone — these are useful for ballpark planning, but candidacy needs to be confirmed in person.

What if you're not a candidate today

Some patients are not candidates today but will be in 2–5 years. The most common reasons:

• Under 25 with progressing loss — wait, document, possibly start medical therapy
• Under 30 with no medical-therapy trial — most BAHRS surgeons will ask you to do 6–12 months on finasteride or minoxidil first
• Donor density borderline — some surgeons will revisit if you stabilise on medical therapy
• Active scalp condition — treat the underlying condition; reassess in 6 months
• Acute telogen effluvium — wait; hair usually regrows on its own

A "no" today is often a "not yet". A reputable UK surgeon will tell you what would change the answer.

Where to start

• Read our Norwood scale guide to estimate your stage
• See hair loss medications for the pre-surgery medical therapy picture
• Browse credentialed UK surgeons for in-person consultation
• See our best UK clinic framework for how to evaluate any quote

References

1. Unger WP. Hair Transplantation. 4th ed. Marcel Dekker; 2004.
2. Shahrabi M, et al. Donor area assessment in FUE: A systematic review. Dermatol Surg. 2022;48(3):320-325.
3. ISHRS. Clinical Practice Guidelines for Hair Restoration. 2026.
4. BAHRS. Patient Selection Criteria for Hair Transplant Surgery in the UK. 2026.
5. Harries MJ, et al. Management of primary cicatricial alopecias. BAD Guidelines. 2021.
6. Heppt MV, et al. Frontal fibrosing alopecia: a review of treatment and surgery. J Eur Acad Dermatol Venereol. 2019;33(5):841-854.
7. Bowe S, et al. The impact of scalp health on transplant outcomes. J Cosmet Dermatol. 2020;19(4):812-817.
8. Malkud S. Telogen Effluvium: A Review. J Clin Diagn Res. 2015;9(9):WE01-WE03.
9. Ludwig E. Br J Dermatol. 1977;97:247-54.
10. Sinclair R, et al. Br J Dermatol. 2005;152:466-73.
11. Goren A, et al. Female pattern hair loss: a clinical review. Dermatol Clin. 2020;38(1):59-66.

This article is pending review by a UK GMC-registered dermatologist or trichologist. The evidence above reflects publicly available peer-reviewed literature and UK regulatory positions as of April 2026.